What is the most appropriate NSAID (including dosing, duration, and gastro‑protection) for treating costochondritis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Best NSAID for Costochondritis

For costochondritis, use ibuprofen 400-800 mg daily (divided doses) or naproxen 500-1000 mg daily for 7-14 days at the lowest effective dose, with mandatory proton pump inhibitor (PPI) co-prescription for patients with any gastrointestinal risk factors, age ≥65 years, or concomitant aspirin use.

Treatment Algorithm

First-Line Approach

Start with acetaminophen (paracetamol) up to 4g daily before considering NSAIDs 1. While less effective than NSAIDs for inflammatory conditions, it has superior cardiovascular and gastrointestinal safety. However, costochondritis often requires NSAID therapy for adequate pain control.

NSAID Selection Strategy

For patients <65 years with no risk factors:

  • Ibuprofen 400-800 mg/day (divided doses) for 2-4 weeks 1
  • Alternative: Naproxen 500-1000 mg/day 2
  • Use the lowest effective dose for the shortest duration 1, 3

For patients ≥65 years or with GI risk factors:

  • Non-selective NSAID (ibuprofen or naproxen) PLUS PPI (omeprazole 20mg daily or equivalent) 1, 4
  • Alternative: COX-2 selective inhibitor (celecoxib 200mg daily) if no cardiovascular risk 1, 3

For patients on aspirin:

  • Avoid ibuprofen (interferes with aspirin's cardioprotective effect) 5
  • Use naproxen or celecoxib PLUS PPI 5, 6

For patients with cardiovascular disease:

  • COX-2 inhibitors are contraindicated 1, 7
  • Use non-selective NSAIDs with extreme caution, limited to 7 days maximum 3
  • Consider topical NSAIDs or alternative therapies

Gastroprotection Requirements

Mandatory PPI co-prescription for:

  • Age ≥65 years 4, 3
  • History of peptic ulcer disease 4, 5
  • Concomitant aspirin, corticosteroids, or anticoagulants 1, 5, 6
  • H. pylori infection (treat first) 5
  • Chronic kidney disease or heart failure 4

PPI reduces NSAID-associated ulcers by 50-90% 1. H2-receptor antagonists at standard doses are inadequate for gastroprotection; only high-dose H2RAs or PPIs provide sufficient protection 2, 5.

Duration and Monitoring

  • Initial treatment: 7-14 days 3, 8
  • Re-evaluate response at 1-2 weeks 1
  • Maximum duration: 3-4 weeks for acute costochondritis 1
  • Monitor for GI symptoms, blood pressure, renal function, and cardiovascular symptoms throughout treatment 4, 3

Critical Pitfalls to Avoid

  1. Never combine multiple NSAIDs (including aspirin as an NSAID) 4, 5
  2. Do not exceed maximum daily acetaminophen dose of 4g when using combination products 4
  3. Avoid COX-2 inhibitors in patients with known cardiovascular disease - they carry significant CV risk 1, 7
  4. Do not use H2-antagonists alone for gastroprotection - they are inadequate except at high doses 2, 5
  5. Age ≥75 years warrants topical NSAIDs over oral when feasible 3

Alternative Considerations

For recurrent or refractory costochondritis, evidence suggests local corticosteroid injections provide significant symptomatic improvement 9, and oral corticosteroids (prednisolone 40mg daily tapered over 3 weeks) show superior pain reduction compared to NSAIDs alone 8. However, these should be reserved for cases inadequately controlled with NSAIDs.

The evidence base for costochondritis specifically is limited, with recommendations extrapolated primarily from osteoarthritis and musculoskeletal pain guidelines 1, 2. The key principle remains: use the lowest effective NSAID dose for the shortest duration with appropriate gastroprotection based on individual risk stratification 1, 3, 5.

References

Guideline

pharmacological management of persistent pain in older persons.

Journal of the American Geriatrics Society (JAGS), 2009

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.